This review highlights the efficacy, safety, and pleiotropic features of lercanidipine, a highly lipophilic dihydropyridine calcium channel antagonist.
Lercanidipine merits consideration in hypertension; leaves open randomized confirmation of pleiotropic benefits.
It is hard to imagine modern medicine without safe drugs (D). Often, adverse drug reactions (ADR) are the reason for drug with drawal, which is quite effective as a whole. The main dihydropyridine calcium channel antagonists (DCCA) ADR are the edema of shin and tachycardia, causing this drug with drawal. Lercanidipine is aquite new member of this class; it is a highly lipophilic compound, which blocking the influx of calcium ions through L-type calcium channels, by maintaining the high intramembrane concentration. This review provides the data on the efficacy and safety of lercanidipine and its pleiotropic features.
No takes yet. Share an insight, caveat, or question.
G S Anikin (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: